SAN DIEGO, April 25, 2017 /PRNewswire/ -- Trovagene,
Inc. (NASDAQ: TROV), a precision medicine biotechnology company,
today announced that its Chief Executive Officer, Bill Welch, will be presenting at the Pioneers
2017 Joseph Gunnar Conference on May 2,
2017 at 4:00 PM EDT at the
Mandarin Oriental in New York
City. Management will also be available to meet with
investors during the conference.
The presentation will be webcast live at
http://wsw.com/webcast/pioneers2/trov and can also be accessed
through the Trovagene investor relations web page at
www.trovagene.com. A replay of the presentation will be
available and archived for 90 days.
About Trovagene, Inc.
Trovagene is a biotechnology company developing oncology
therapeutics for improved cancer care by leveraging its proprietary
Precision Cancer Monitoring® (PCM) technology in tumor
genomics. Trovagene has broad intellectual property and
proprietary technology to measure circulating tumor DNA (ctDNA) in
urine and blood to identify and quantify clinically actionable
markers for predicting response to cancer therapies.
Trovagene offers its PCM technology at its CLIA/CAP – accredited
laboratory and plans to continue to vertically integrate its PCM
technology with precision cancer therapeutics. For more
information, please visit www.trovagene.com.
Trovagene Contact
Vicki Kelemen
Sr. Director, Communications
858-952-7652
vkelemen@trovagene.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/trovagene-to-present-at-the-pioneers-2017-joseph-gunnar-conference-on-may-2-2017-in-new-york-city-300444635.html
SOURCE Trovagene, Inc.